Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex
FRANCE

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02


Url canonique : www.lavoisier.fr/livre/autre/prostate-cancer-screening-2nd-ed/pauler/descriptif_3215731
Url courte ou permalien : www.lavoisier.fr/livre/notice.asp?ouvrage=3215731

0 article 

 Frais de port 0,01€*

Exclusivité web : à partir de 35 euros d’achat, frais de port à 1 centime pour les expéditions vers la France métropolitaine, la Suisse et l’UE avec Colissimo ou GLS

L’édition demandée n’est plus disponible, nous vous proposons la dernière édition.

Prostate Cancer Screening (2nd Ed., 2nd ed. 2009) Second Edition Current Clinical Urology Series

Langue : Anglais

Coordonnateurs : Pauler Ankerst Donna, Tangen Catherine M., Thompson Ian M.

Couverture de l’ouvrage Prostate Cancer Screening

More than one in six men will develop prostate cancer in their lifetime. In recent years there has been an explosion of information regarding PSA screening and biomarkers for the disease. In Prostate Cancer Screening, Second Edition, the world?s leading experts on prostate cancer detection update the first edition with the latest findings. The book incorporates a series of thoughtful and cutting-edge works from the world?s experts in prostate cancer screening, ranging from the current status quo of prostate cancer screening across the globe to consensus on optimal utilization of the traditional PSA and DRE tests, to cutting-edge research in new biomarkers, biomeasures, and extended risk algorithms for prostate cancer. An additional chapter covers family-based linkage analysis as well as possible pitfalls in prostate cancer biomarker evaluation studies. Timely and authoritative, Prostate Cancer Screening, Second Edition, is an essential text for urologists, oncologists and family physicians, as well as researchers in the biomarker industry who seek methods to better develop and support markers and measures of prostate cancer.

Trends in Prostate Cancer Screening.- Overview of US Prostate Cancer Trends in the Era of PSA Screening.- Trends in Prostate Cancer Screening: Overview of the UK.- Trends in Prostate Cancer Screening: Canada.- Trends in Prostate Cancer Screening – Overview of Europe.- Prostate-Specific Antigen.- Evolution of Prostate-Specific Antigen for Screening.- The Performance Characteristics of Prostate-Specific Antigen for Prostate Cancer Screening.- The Performance of PSA for Predicting Prostate Cancer After a Prior Negative Prostate Biopsy.- Subfractions and Derivatives of Total Prostate-Specific Antigen in the Early Detection of Prostate Cancer.- PSA Velocity at Presentation as a Predictor of Prostate Cancer Aggressiveness.- Risk Assessment for Prostate Cancer.- Nomograms for Prostate Cancer.- Decision Aid Criteria and Artificial Neural Networks for Optimizing Prostate Cancer Risk Prediction.- Development of the Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator.- Integration of Risk Assessment in Prostate Cancer Screening.- Family History of Prostate Cancer During Rapidly Increasing Incidence.- Recent Biomarkers for Prostate Cancer.- PSA Isoforms: [?2]proPSA Significant Adjunct to Free PSA.- PCA3.- Transcriptional Profiling of Prostate Cancer: Biomarker Identification and Clinical Applications.- Biomarkers for Prostate Cancer Detection: Family-Based Linkage Analysis and Case–Control Association Studies.- GSTP1 Hypermethylation for Prostate Cancer Detection.- EPCA and EPCA-2 as Potential Biomarkers for Prostate Cancer Detection.- Design and Methodologic Considerations in Biomarker Studies.- Toward a Robust System for Biomarker Triage and Validation – EDRN Experience.- Statistical Evaluation of Markers and Risk Tools for Prostate Cancer Classification andPrediction.- Pitfalls in Prostate Cancer Biomarker Evaluation Studies.- Building upon Recently Completed and Ongoing Prospective Trials.- Prostate-Specific Antigen and Its Role on the Prostate Cancer Prevention Trial.- The Selenium and Vitamin E Cancer Prevention Trial.- PLCO: A Randomized Controlled Screening Trial for Prostate, Lung, Colorectal, and Ovarian Cancer.- The European Randomized Study of Screening for Prostate Cancer (ERSPC).
Comprehensively reviews every aspect of prostate cancer screening, including the latest discoveries in biomarker research Outlines current screening policies by continent and presents the relative ongoing prospective screening trials around the globe Includes supplementary material: sn.pub/extras

Date de parution :

Ouvrage de 397 p.

17.8x25.4 cm

Disponible chez l'éditeur (délai d'approvisionnement : 15 jours).

232,09 €

Ajouter au panier

Ouvrage de 397 p.

17.8x25.4 cm

Sous réserve de disponibilité chez l'éditeur.

Prix indicatif 210,99 €

Ajouter au panier